Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

Gina Ma, Yi Wang, Tahmeena Ahmed, Ann Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Shafic Salman

Research output: Contribution to journalArticle

Abstract

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

Original languageEnglish (US)
Pages (from-to)42-44
Number of pages3
JournalLeukemia Research Reports
Volume9
DOIs
StatePublished - Jan 1 2018

Fingerprint

CD19 Antigens
Antigen Receptors
Acute Myeloid Leukemia
Leukemia
Phenotype
Neoplasms
B-Lymphocytes
Technology

Keywords

  • Acute myeloid leukemia
  • Chimeric antigen receptors
  • Immunotherapy
  • Mixed phenotype acute leukemia
  • T cells

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ma, G., Wang, Y., Ahmed, T., Zaslav, A. L., Hogan, L., Avila, C., ... Salman, H. S. (2018). Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia. Leukemia Research Reports, 9, 42-44. https://doi.org/10.1016/j.lrr.2018.03.002

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia. / Ma, Gina; Wang, Yi; Ahmed, Tahmeena; Zaslav, Ann Leslie; Hogan, Laura; Avila, Cecilia; Wada, Masayuki; Salman, Huda Shafic.

In: Leukemia Research Reports, Vol. 9, 01.01.2018, p. 42-44.

Research output: Contribution to journalArticle

Ma, G, Wang, Y, Ahmed, T, Zaslav, AL, Hogan, L, Avila, C, Wada, M & Salman, HS 2018, 'Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia', Leukemia Research Reports, vol. 9, pp. 42-44. https://doi.org/10.1016/j.lrr.2018.03.002
Ma, Gina ; Wang, Yi ; Ahmed, Tahmeena ; Zaslav, Ann Leslie ; Hogan, Laura ; Avila, Cecilia ; Wada, Masayuki ; Salman, Huda Shafic. / Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia. In: Leukemia Research Reports. 2018 ; Vol. 9. pp. 42-44.
@article{ac95363c478547c7b1d25888bcf5bb84,
title = "Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia",
abstract = "Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.",
keywords = "Acute myeloid leukemia, Chimeric antigen receptors, Immunotherapy, Mixed phenotype acute leukemia, T cells",
author = "Gina Ma and Yi Wang and Tahmeena Ahmed and Zaslav, {Ann Leslie} and Laura Hogan and Cecilia Avila and Masayuki Wada and Salman, {Huda Shafic}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.lrr.2018.03.002",
language = "English (US)",
volume = "9",
pages = "42--44",
journal = "Leukemia Research Reports",
issn = "2213-0489",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia

AU - Ma, Gina

AU - Wang, Yi

AU - Ahmed, Tahmeena

AU - Zaslav, Ann Leslie

AU - Hogan, Laura

AU - Avila, Cecilia

AU - Wada, Masayuki

AU - Salman, Huda Shafic

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

AB - Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

KW - Acute myeloid leukemia

KW - Chimeric antigen receptors

KW - Immunotherapy

KW - Mixed phenotype acute leukemia

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85045192515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045192515&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2018.03.002

DO - 10.1016/j.lrr.2018.03.002

M3 - Article

AN - SCOPUS:85045192515

VL - 9

SP - 42

EP - 44

JO - Leukemia Research Reports

JF - Leukemia Research Reports

SN - 2213-0489

ER -